Company news

Mesoblast Limited news in 2016

Mesoblast Limited's news releases, calls and decks from 2016, newest first.

View company

Key US Patent Granted For Heart, Stroke, Vascular Diseases

February 10, 2016

Key USA Patents Increase Commercial Rights and Indications

February 10, 2016

Key Patent Allowed In Japan For Heart Diseases, Stroke

February 10, 2016

Key Mesoblast Patent Claims Upheld in Europe

February 10, 2016

Key Mesenchymal Precursor Cell Patent Granted in Japan

February 10, 2016

Key Manufacturing Agreement with FDA for Phase 3 Trials

February 10, 2016

Improved Survival in Children with GvHD After Cell Therapy

February 10, 2016

Full Japanese Approval For MSC Product

February 10, 2016

FDA Clears Phase 3 Heart Failure Trial

February 10, 2016

FDA clears phase 2 clinical trial for rheumatoid arthritis

February 10, 2016

Fast Track Access To Potential Japan Investment Incentives

February 10, 2016

Diabetic Nephropathy Results To Be Presented At ADA Meeting

February 10, 2016

Circulation Research Publishes AMI Preclinical Trial Results

February 10, 2016

Chronic Low Back Pain Results Presented at NASS

February 10, 2016

CHF Phase 2 Trial Results Published In Circulation Research

February 10, 2016

Celgene And Mesoblast Extend Agreement

February 10, 2016

Celgene And Mesoblast Enter Into Agreement

February 10, 2016

Angioblast Stockholders Approve Acquisition By Mesoblast

February 10, 2016

← Newer news releases

Decks in 2016